Our Life Sciences Manufacturing Portfolio

Anne Kantardjieff, PhD, is Vice President and Head of CMC Development and Regulatory for Biologics and Advanced Therapies at Biogen. She is a seasoned biopharmaceutical executive with over 15 years of experience advancing complex biologics and cell and gene therapies from early development through global commercialization.

Anne is recognized across the industry for her expertise in CMC strategy, manufacturing scalability, and regulatory integration for advanced modalities. She leads global teams responsible for development, technical transfer, and regulatory CMC strategy across a diverse portfolio of biologics and ATMP programs, partnering closely with R&D, Quality, and Commercial Operations to enable reliable, inspection-ready supply and accelerated patient access.

Prior to Biogen, Anne served as Vice President of Manufacturing and MSAT at bluebird bio, where she led end-to-end supply and technical operations for four commercially approved autologous gene therapies—Zynteglo, Skysona, Abecma, and Lyfgenia. In this role, she oversaw external manufacturing partnerships, process validation, regulatory inspections, and commercial launch execution across multiple global markets.

Earlier in her career at bluebird bio, Anne drove strategic process improvements, expanded manufacturing capacity, and played a pivotal role in successful product approvals. She previously held leadership roles at Alexion Pharmaceuticals, where she led early- and late-stage process development teams and contributed to the commercialization of Strensiq, Kanuma, and Ultomiris.

Anne is known for building high-performing, collaborative organizations and integrating technical rigor with strategic decision-making to modernize manufacturing platforms and enable modality agility.

She holds a PhD in Chemical Engineering from the University of Minnesota and a Bachelor of Engineering in Chemical Engineering from McGill University. She is widely published and has held leadership roles within the American Chemical Society’s Biochemical Technology Division.